Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
---|---|---|---|---|
24008 | RNK-05047 | 2503036-46-0 | ≧98.0% | |
RNK-05047 is a PROTAC degrader of BRD4 which displays significant tumor growth inhibi | ||||
20655 | (R)-Praziquantel | 57452-98-9 | 98% Min. | |
(R)-Praziquantel is an active enantiomer of praziquantel that acts as a potent anthel | ||||
20652 | Resminostat | 864814-88-0 | 98% Min. | |
Resminostat, also known as 4S-201 and RAS2410, is an orally bioavailable inhibitor of | ||||
20627 | Resigratinib | 2750709-91-0 | 98% Min. | |
Resigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor and ant | ||||
20621 | Risvodetinib | 2031185-00-7 | 98% Min. | |
Risvodetinib, also known as IkT-148009., is a brain-penetrant c-Abl inhibitor with a | ||||
20595 | Ropidoxuridine | 93265-81-7 | 98% Min. | |
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, | ||||
20526 | RPT193 | 2366152-15-8 | 98% Min. | |
230403 | (R,S)-BI 1015550 | 1423719-27-0 | ≧98.0% | |
BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of P | ||||
233901 | RRX-001 | 925206-65-1 | ≧98.0% | |
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor a | ||||
20460 | Ro5-3335 | 30195-30-3 | ≧98.0% | |
Ro5-3335 is a lipophilic small molecule RUNX1 inhibitor. | ||||
20452 | Ritlecitinib tosylate | 2192215-81-7 | 98% Min. | |
Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor. PF | ||||
2320201 | Ro 24-7429 | 139339-45-0 | ≧98.0% | |
Ro24-7429 is a potent and orally activeHIV-1transactivator proteinTatantagonist. Ro24 | ||||
822224 | RP-5063(Brilaroxazine) | 1239729-06-6 | ≧98.0% | |
RP-5063(Brilaroxazine) is a multimodal modulator of serotonin and dopamine recept | ||||
20316 | Rucaparib Camsylate | 1859053-21-6 | 98% Min. | |
Rucaparib camsylate is a potent, orally available inhibitor of poly ADP-ribose polyme | ||||
21235 | Rhosin hydrochloride | 1281870-42-5 | 98% Min. | |
20123102 | (R,Z)-1-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino) quinazolin-6-yl)but-2-yn-1-one O-morpholin-3-ylmethyl oxime | 1831116-75-6 | 98% Min. | |
201221 | Razuprotafib sodium | 1809275-69-1 | ≧98.0% | |
Razuprotafib, also known as AKB-9778, is a small molecule inhibitor of vascular endot | ||||
20102901 | Razuprotafib | 1008510-37-9 | ≧98.0% | |
Razuprotafib, also known as AKB-9778, is a small molecule inhibitor of vascular endot | ||||
2073103 | Remibrutinib ( LOU064 ) | 1787294-07-8 | 98% Min. | |
Remibrutinib ( LOU064 ) is a Potent and Highly Selective Covalent Inhibitor of Bruton | ||||
2071545 | Remdesivir | 1809249-37-3 | 98% Min. | |
Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside anal | ||||
2071520 | RK-287107 | 2171386-10-8 | 98% Min. | |
RK-287107 is a potent TNKS/TNKS2 inhibitor (IC50 = 14.4 nM) with >7000-fold select | ||||
207101 | RBN-2397 | 2381037-82-5 | 98% Min. | |
2062334 | (2R,6S)-tert-butyl 4-(4-aminobenzoyl)-2,6-dimethylpiperazine-1-carboxylate | 2161337-98-8 | 98% Min. | |
202329 | (R)-methyl 2-(tert-butyldimethylsilyloxy)propanoate | 171230-81-2 | 98% Min. | |
2062017 | 3-[(2RS)-tetrahydro-2H-pyran-2-yloxy]propanoic acid | 1221443-23-7 | 96% Min. | |
2062004 | ((1R,2S)-2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl)methyl acetate | 1369768-29-5 | ≧95.0% | |
690120 | Rigosertib | 592542-59-1 | 98% Min. | |
Rigosertib(ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, w | ||||
206102 | Resatorvid | 243984-11-4 | 98% Min. | |
Resatorvid, also known as TAK-242, is a cell-permeable inhibitor of TLR4 signaling, b | ||||
204503 | RU320521 | 2262452-06-0 | 98% Min. | |
RU320521, also known as RU521; RU.521 is a potent and selective inhibitor of cGAS, in | ||||
580586 | (R)-tert-butyl 2-(2-ethynyl-2-methylpyrrolidin-1-yl)acetate | 2086689-88-3 | >96% | |
(R)-tert-butyl 2-(2-ethynyl-2-methylpyrrolidin-1-yl)acetate, CAS 2086689-88-3, is a v |
Overnight Delivery
Fast & Safe Delivery Worldwide
Safety and Security
Intimate Service
Copyright 2015-2022 武汉永璨生物科技有限公司 版权所有 | 鄂ICP备17005301号-1